Autosomal Dominant Polycystic Kidney Disease (ADPKD)

The Montefiore / Einstein Division of  Nephrology offers comprehensive renal care for patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Patients receive ongoing chronic kidney disease management (CKD) as well as evaluation for treatment with tolvaptan (Jynarque) which is FDA approved to slow the progression of renal disease for eligible ADPKD patients.  Patients who are eligible for tolvaptan therapy are actively supported and monitored through our ADPKD Program.

Polycystic Kidney

Raeleen De Jesus, DNP, is a Nurse Practitioner at the Nephrology Department at Montefiore Medical Center. She is the coordinator of the Montefiore Einstein Autosomal Dominant Polycystic Kidney Disease Program and practices in Montefiore’s outreach clinics. Her clinical focus is in chronic kidney disease, end stage kidney disease, nephrolithiasis, and autosomal dominant polycystic kidney disease.

In 2006, NP De Jesus graduated from Rutgers University with her Bachelor of Science in Nursing. She initially practiced as a clinical nurse in medical-surgical and cardiothoracic intensive care units. In 2011, NP De Jesus graduated from Rutgers University with her Master of Science in Nursing. She then practiced as a nurse practitioner in Bayonne, NJ. NP De Jesus joined Montefiore Medical Center in 2016 under the Urology Department with a focus on nephrolithiasis.  She earned her Doctor of Nursing Practice degree from Wilkes University in 2018. In 2020, NP De Jesus joined the Nephrology department.

NP De Jesus is board certified as an Adult Nurse Practitioner under the American Nurses Credentialing Center.

Call 1-866-633-8255 to schedule a new ADPKD patient visit with Dr. Amanda Raff or Dr. Maryanne Sourial.